We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App

Novel Test to Ensure Essential Treatment for Newborns with Serious Genetic Disease

By LabMedica International staff writers
Posted on 16 Mar 2023
Print article
Image: A new test could greatly improve quality of life for infants with homocystinuria (Photo courtesy of Pexels)
Image: A new test could greatly improve quality of life for infants with homocystinuria (Photo courtesy of Pexels)

Homocystinuria (HCU) is a congenital disease that if left untreated could lead to severe complications. HCU affects an infant's ability to metabolize the amino acid methionine, which is an essential protein component found in breast milk. This leads to an abnormal increase in levels of methionine and another amino acid known as homocysteine, which, in turn, could cause complications ranging from skeletal and eye problems to intellectual disabilities and vascular abnormalities. Early detection and treatment of HCU can prevent these complications. However, current tests only gauge methionine levels, which remain low during newborn screening. Thus, around 50% of HCU cases remain unidentified, leaving them at high risk of going untreated.

Scientists at the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) have developed a new test that could markedly enhance the quality of life for infants with HCU and also demonstrated its efficacy. In newborns with HCU, homocysteine levels exhibit an early, significant rise - generally before methionine levels - which makes it an ideal marker for detecting the disease during the first few days of life when screening is performed. This makes homocysteine a better early marker of HCU in infants.

The research team evaluated the performance of the test by using it to screen residual newborn screening specimens procured from infants who had already received HCU diagnoses. The specimens included 100 samples from healthy infants, 50 samples from HCU-negative infants receiving total parenteral nutrition (TPN) in the NICU, and two samples from HCU-positive infants. Impressively, the test effectively distinguished between healthy and HCU-positive samples. Additionally, the specimens procured from infants receiving TPN treatment were accurately classified as HCU-negative, which is crucial because traditional methionine tests for HCU tend to produce a high number of false positives in babies receiving TPN.

“Here we present the only flow injection analysis–tandem mass spectrometry first-tier newborn screening method that directly quantifies total homocysteine from dried blood spots,” said Konstantinos Petritis, Ph.D., at the CDC who led the group of researchers. “The ability to screen total homocysteine during first-tier newborn screening is a significant step toward reducing HCU false-negative rates, which will enable early identification and intervention to reduce HCU-associated morbidity and mortality.”

Related Links:

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Hemoglobin Testing System

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.